Product Description: Nerelimomab (BAYX1351) is an anti-TNF-α antibody. Nerelimomab can be used for research of sepsis[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Schlag G, et al. Anti-tumor necrosis factor antibody treatment of recurrent bacteremia in a baboon model. Shock. 1994 Jul;2(1):10-8; discussion 19-22. /[2]Cohen J, et al. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med. 1996 Sep;24(9):1431-40.
CAS Number: 162774-06-3
Molecular Weight: N/A
Research Area: Infection
Solubility: 10 mM in DMSO
Target: TNF Receptor